30 completed, 8 unknown, 2 not yet recruiting, 2 recruiting. 45 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 45 | Completed 30, Unknown 8, Not yet recruiting 2, Recruiting 2, Withdrawn 2, Terminated 1 |
Follow Metaplasia: new trials by email Literature Review of Metaplasia trials Research Report on Metaplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV) Aflibercept Intravitreous Injection - Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD) | Phase 4 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 174 | 2026-01-01 | 2026-01-26 |
| Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization Intravitreal faricimab injection - Age-related Macular Degeneration (ARMD), Choroidal Neovascularization | Phase 4 | Not yet recruiting | Kim's Eye Hospital | 30 | 2025-09-23 | 2025-09-23 |
| Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration Faricimab Injection [Vabysmo] - Macular Degeneration Choroidal Neovascularization | Phase 4 | Recruiting | Hospital Authority, Hong Kong | 40 | 2025-08-21 | 2025-10-01 |
| Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO) Faricimab Injection [Vabysmo] - Polypoidal Choroidal Vasculopathy | Phase 4 | Recruiting | Association for Innovation and Biomedical Research on Light and Image | 120 | 2025-08-06 | 2026-02-06 |
| Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment Aflibercept 8mg - Age-related Macular Degeneration (ARMD) | Phase 4 | Completed | Kim's Eye Hospital | 35 | 2024-10-21 | 2026-07-16 |
| Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) Injection Brolucizumab - Neovascular Age-related Macular Degeneration (nAMD) | Phase 4 | Completed | Novartis Pharmaceuticals | 105 | 2022-03-09 | 2025-03-20 |
| Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab. Brolucizumab - Neovascular Age-related Macular Degeneration | Phase 4 | Completed | Novartis Pharmaceuticals | 122 | 2021-10-15 | 2025-05-16 |
| Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period Bromfenac Sodium 0.07%, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly, Propylene Glycol Preservative-free Artificial Tears - Vein Occlusion, Macular Degeneration Choroidal Neovascularization | Phase 4 | Completed | Retina Research Institute, LLC | 77 | 2021-08-20 | 2025-07-29 |
| Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration Brolucizumab - Age-related Macular Degeneration | Phase 4 | Completed | Novartis Pharmaceuticals | 52 | 2021-07-13 | 2025-09-26 |
| Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy OCTA plus OCT guided 3+PRN regimen, OCT guided 3+PRN regimen, Anti-VEGF drug - Polypoidal Choroidal Vasculopathy | Phase 4 | Unknown | Xiaodong Sun | 102 | 2020-06-01 | 2020-05-08 |
| An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Treat and Extend with Aflibercept 2mg, Fixed Dosing with Aflibercept 2mg - Age Related Macular Degeneration, Polypoidal Choroidal Vasculopathy | Phase 4 | Completed | Singapore National Eye Centre | 54 | 2017-12-01 | 2021-08-18 |
| Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy Triamcinolone Acetonide, Ranibizumab - Wet Macular Degeneration | Phase 4 | Unknown | Aier School of Ophthalmology, Central South University | 120 | 2017-01-01 | 2018-11-30 |
| Initial Versus Delayed PDT Combination With Conbercept in PCV conbercept, Initial PDT, Delayed PDT - Polypoidal Choroidal Vasculopathy | Phase 4 | Completed | The Eye Hospital of Wenzhou Medical University | 80 | 2017-01-01 | 2019-07-19 |
| Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy ranibizumab - Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy | Phase 4 | Unknown | Pusan National University Hospital | 28 | 2016-11-22 | 2019-10-10 |
| CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab Ranibizumab - Wet Age-related Macular Degeneration (Wet AMD) | Phase 4 | Withdrawn | Novartis Pharmaceuticals | 2016-03-01 | 2017-02-15 | |
| Strategies for Management of Corneal Neovascularisation Fine Needle Diathermy, Bevacizumab - Corneal Neovascularisation | Phase 4 | Unknown | University of Nottingham | 40 | 2015-12-01 | 2015-12-02 |
| Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy Intravitreal Aflibercept - Polypoidal Choroidal Vasculopathy | Phase 4 | Completed | Association for Innovation and Biomedical Research on Light and Image | 50 | 2015-11-23 | 2020-01-10 |
| The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV) Conbercept - Polypoidal Choroidal Vasculopathy (PCV) | Phase 4 | Unknown | Chengdu Kanghong Biotech Co., Ltd. | 300 | 2015-10-01 | 2017-07-19 |
| Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization 0.5mg intravitreal ranibizumab - Choroidal Neovascularization | Phase 4 | Completed | Zhongshan Ophthalmic Center, Sun Yat-sen University | 54 | 2015-04-01 | 2019-03-11 |
| EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection Intravitreal aflibercept injection - Macular Degeneration, Wet Macular Degeneration | Phase 4 | Completed | University of California, San Diego | 50 | 2014-04-01 | 2021-03-25 |
Showing 20 of 45. Sign in to see all of them.
Choroidal Neovascularization (22) · Macular Degeneration (20) · Polypoidal Choroidal Vasculopathy (14) · Neovascularization, Pathologic (6) · Wet Macular Degeneration (6) · Vision Disorders (4) · Geographic Atrophy (3) · Macular Edema (3) · Myopia (3) · Retinal Degeneration (3) · Retinal Diseases (3) · Retinal Neovascularization (3) · Corneal Neovascularization (2) · Diabetic Retinopathy (2) · Eye Diseases (2)
Pathologic Processes (45) · Pathological Conditions, Signs and Symptoms (45) · Eye Diseases (42) · Neovascularization, Pathologic (39) · Choroid Diseases (35) · Uveal Diseases (35) · Retinal Diseases (24) · Retinal Degeneration (21) · Choroidal Neovascularization (13) · Cardiovascular Diseases (4) · Macular Degeneration (4) · Nervous System Diseases (4) · Neurologic Manifestations (4) · Sensation Disorders (4)
Ranibizumab (18) · aflibercept (6) · Verteporfin (5) · Bevacizumab (3) · Coal Tar (2) · Injections (2) · KH902 fusion protein (2) · brolucizumab (2) · faricimab (2) · Dexamethasone (1) · Intravitreal Injections (1) · Ketorolac (1) · Loteprednol Etabonate (1) · Sodium Chloride (1) · Triamcinolone (1)
Novartis Pharmaceuticals (7) · Instituto de Olhos de Goiania (4) · Novartis (3) · Pusan National University Hospital (3) · Association for Innovation and Biomedical Research on Light and Image (2) · Kim's Eye Hospital (2) · Vista Klinik (2) · Aier School of Ophthalmology, Central South University (1) · Brandon G. Busbee, MD (1) · Chengdu Kanghong Biotech Co., Ltd. (1) · Federal University of São Paulo (1) · Gregg T. Kokame, MD (1) · Hospital Authority, Hong Kong (1) · Moorfields Eye Hospital NHS Foundation Trust (1) · Oklahoma State University Center for Health Sciences (1)
South Korea (7) · China (6) · United States (6) · Brazil (5) · Germany (4) · Italy (4) · Portugal (4) · Spain (4) · Switzerland (4) · United Kingdom (4) · Belgium (3) · Hong Kong (3) · Singapore (3) · Turkey (Türkiye) (3) · Australia (2)
Christian Pruente, MD (2) · Andrea Russo, MD (1) · Belquiz A Nassaralla, PhD (1) · Brandon G Busbee, MD (1) · Francesco Semeraro, Professor (1) · Gemmy Cheung (1) · Gregg T. Kokame, MD, MMS (1) · Harminder S Dua, Professor (1) · Jae Pil Shin, MD, PhD (1) · James W Bainbridge, MA PhD FRCOphth (1) · Ji Eun Lee, MD, PhD (1) · Ji Eun Lee, MH, PhD (1) · Joao J Nassaralla, Jr (1) · Joao J Nassaralla, PhD (1)
PMID 11297486, PMID 11642370, PMID 12967792, PMID 17188044, PMID 17675159, PMID 18301024, PMID 1850220, PMID 1922252, PMID 19365036, PMID 19592101, PMID 20110127, PMID 22264944, PMID 22426346, PMID 22559899, PMID 22562296, PMID 22801846, PMID 22872673, PMID 23021093, PMID 23084240, PMID 23245386, PMID 23317655, PMID 25758601, PMID 25981599, PMID 27442130, PMID 27465105, PMID 28005662, PMID 28851779, PMID 28983556, PMID 29019795, PMID 29979454, PMID 30136868, PMID 30550528, PMID 30581602, PMID 30918819, PMID 30986442, PMID 32107066, PMID 32199867, PMID 32672800, PMID 33136977, PMID 33470281, PMID 33574033, PMID 34348351, PMID 35085502, PMID 35188581, PMID 35223882, PMID 35887936, PMID 36246941, PMID 36977322, PMID 37260074, PMID 37535382
2015 (1), 2019 (1)